FDA approves tesamorelin for HIV patients with lipodystrophy
Canada-based Theratechnologies announced that FDA has approved tesamorelin (Egrifta) to treat HIV patients with lipodystrophy. The condition is associated with many antiretroviral drugs used to treat HIV.
Canada-based Theratechnologies announced that FDA has approved tesamorelin (Egrifta) to treat HIV patients with lipodystrophy. The condition is associated with many antiretroviral drugs used to treat HIV.
Tesamorelin is the first FDA-approved treatment for lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs. It is a growth hormone releasing factor drug that is administered in a once-daily injection.
FDA’s approval of tesamorelin was based on 2 clinical trials involving 816 HIV-infected adults with lipodystrophy and excess abdominal fat. In both studies, patients treated with tesamorelin experienced greater reductions in abdominal fat as measured by CT scan, compared with patients receiving a placebo. Some patients using tesamorelin reported improvements in their self-image.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
